Belgian drug discovery firm Galapagos NV and Boston, USA-based Cellzome have entered a kinase drug discovery collaboration. Under the terms of the deal, Galapagos' service division, BioFocus DPI, will give Cellzome access to its SoftFocus kinase libraries and provide biological screening and chemistry expertise to find inhibitors of Cellzome's kinase targets. In this service contract, BioFocus DPI will receive an upfront payment for the library access as well as research fees. Further financial terms of the agreement were not dicslosed.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze